Nasal immune gene expression in response to azelastine and fluticasone propionate combination or monotherapy

Annabelle M. Watts1 | Nicholas P. West1,2 | Peter K. Smith3 | Ping Zhang2 | Allan W. Cripps2,4 | Amanda J. Cox1,2

1School of Medical Science, Griffith University, Southport, Queensland, Australia
2Menzies Health Institute of Queensland, Griffith University, Southport, Queensland, Australia
3Queensland Allergy Services Clinic, Southport, Queensland, Australia
4School of Medicine, Griffith University, Southport, Queensland, Australia

Correspondence
Amanda J. Cox, Menzies Health Institute Queensland, Griffith University, Parklands Dr, Southport, QLD 4215, Australia.
Email: a.cox@griffith.edu.au

Funding information
Mylan N.V.

Abstract

Background: The combination of the antihistamine azelastine (AZE) with the corticosteroid fluticasone propionate (FP) in a single spray, has been reported to be significantly more effective at reducing allergic rhinitis (AR) symptoms than treatment with either corticosteroid or antihistamine monotherapy. However, the biological basis for enhanced symptom relief is not known. This study aimed to compare gene expression profiles (760 immune genes, performed with the NanoString nCounter) from peripheral blood and nasal brushing/lavage lysate samples in response to nasal spray treatment.

Methods: Moderate/severe persistent dust mite AR sufferers received either AZE (125 μg/spray) nasal spray (n = 16), FP (50 μg/spray) nasal spray (n = 14) or combination spray AZE/FP (125 μg AZE and 50 μg FP/spray) (n = 14) for 7 days, twice daily. Self-reported symptom questionnaires were completed daily for the study duration. Gene expression analysis (760 immune genes) was performed with the NanoString nCounter on purified RNA from peripheral blood and nasal brushing/lavage lysate samples.

Results: In nasal samples, 206 genes were significantly differentially expressed following FP treatment; 182 genes downregulated (−2.57 to −0.45 Log2 fold change [FC]), 24 genes upregulated (0.49–1.40 Log2 FC). In response to AZE/FP, only 16 genes were significantly differentially expressed; 10 genes downregulated (−1.53 to −0.58 Log2 FC), six genes upregulated (1.07–1.62 Log2 FC). Following AZE treatment only five genes were significantly differentially expressed; one gene downregulated (−1.68 Log2 FC), four genes upregulated (0.59–1.19 Log2 FC). Immune gene changes in peripheral blood samples following treatment were minimal. AR symptoms improved under all treatments, but improvements were less pronounced following AZE treatment.

Conclusion: AZE/FP, FP, and AZE had diverse effects on immune gene expression profiles in nasal mucosa samples. The moderate number of genes...
modulated by AZE/FP indicates alternative pathways in reducing AR symptoms whilst avoiding extensive local immune suppression.

**KEYWORDS**
allergic rhinitis, gene expression, mucosa, nasal spray

1 | INTRODUCTION

Allergic rhinitis (AR) is associated with significant global medical and economic burden.¹⁻³ Intranasal antihistamines and corticosteroids are first-line treatments for AR management. A combination spray is available for moderate-to-severe AR sufferers who require multiple therapies to achieve symptomatic relief.⁴ Clinical trials comparing each active agent (antihistamine or corticosteroid) versus the combination therapy, have demonstrated that the combination spray was more effective than either monotherapy at reducing AR symptoms.⁵⁻⁹ As antihistamines and corticosteroids have distinct mechanisms of action, potential additive, or synergistic effects may contribute to the enhanced symptomatic relief observed. Experimental studies examining the mechanism of action behind these enhanced effects are limited. The purpose of this study was to investigate the potential mechanisms through which antihistamine and corticosteroid nasal sprays provide relief from AR symptoms and to determine if combining an antihistamine and corticosteroid provides any synergistic effects on gene expression profiles in the nasal mucosa and blood samples.

2 | METHODS

2.1 | Study design

This study was a randomized, double-blind, three-armed parallel-group study where combination therapy was compared against single active ingredients as control groups. Clinical assessments were conducted at the Queensland Allergy Services Clinic (Gold Coast, Australia) and the Clinical Trial Unit at Griffith University (Gold Coast, Australia) from November 2016 to May 2018. Participants attended a screening visit (Day 14) for evaluation of allergen sensitivities and provision of blood samples. Following screening, eligible participants were instructed to complete a 14-day washout period and cease use of all intranasal and immune modulating medications. Participants were advised to use the following as rescue medication in the event of a considerable symptomatic episode: (1) nasal irrigation with saline solution, (2) oral decongestants, and (3) oral antihistamines. Participants were requested not to take any allergy medications in 48 h before the screening (Day 14) and baseline (Day 0).

At baseline, participants provided nasal lavage/brush and blood samples for gene expression analysis. Participants were randomized using a block randomization method stratified by allergen sensitivity (dust mite only or dust mite and grass allergy) and sex to one of three treatment groups (1) Azep® nasal spray [Mylan Health Pty Ltd], azelastine (AZE) 125 µg/spray, (2) Flixonase® nasal spray [Mylan Health Pty Ltd], fluticasone propionate (FP) 50 µg/spray, or (3) Dymista® nasal spray [Mylan Health Pty Ltd], 125 µg of azelastine, and 50 µg fluticasone propionate/spray (AZE/FP). Participants were instructed to administer the allocated nasal spray (provided in a sealed envelope to maintain blinding) 1 spray per nostril, twice daily, for 7 days. Participants were discouraged from using any allergy medications other than the study medication during the treatment period. Following the treatment period, participants returned for the final visit (Day 7) for the provision of nasal lavage/brushing and blood samples. Participant compliance was assessed based on a self-report of the number of doses missed and was also estimated by measuring the amount of study medication remaining (by weight) relative to the amount (weight) before dispensing.

This study was approved by the Griffith University Human Research Ethics Committee (Ref:2016/279) and was registered with the Australian and New Zealand Clinical Trial Registry (ACTRN12616001439437) before commencement. All participants provided written and informed consent before participation.

2.2 | Participant selection: Inclusion and exclusion criteria

Men and women, 18–65 years of age, with a more than 2-year history of moderate-severe AR (as defined by the Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines)¹⁰ were recruited to the study. Participants were also required to have a Total Nasal Symptom Score (TNSS)¹¹ of at least six, a score of at least 50 mm on a Visual Analog Scale (VAS) for overall symptom severity¹² in the previous 24 h, and a positive allergic response to dust mites determined with a skin prick test and/or
serum specific IgE radioallergosorbent test (RAST) (QML Pathology, Murarrie, Queensland, Australia) to Derma-

tophagoides pteronyssinus or D. farinae.

Individuals suffering from nonallergic rhinitis; who consumed probiotics in the previous 12 weeks, used oral
corticosteroids within the previous 6 months or antibi-
otics within the previous 30 days; used anti-
inflammatory/immune-modulating medications; had the
existing respiratory disease (including asthma, nasal
polyposis, or chronic obstructive pulmonary disorder);
had existing immune dysfunction (other than allergies);
had recent nasal surgery/trauma that could affect sam-
ping; were ill at time of enrollment; reported hepatic
impairment or excessive alcohol consumption13; had
known hypersensitivity to steroids or antihistamines; or
were pregnant at the time of enrolment were excluded
from participating.

2.3 | Symptom assessment

Participants completed the mini Rhinoconjunctivitis
Quality of Life Questionnaire (mRQLQ)14 at the begin-
ning and end of the intervention and maintained a symptom
and medication diary (SMD) daily for the duration of the
study. The SMD consisted of three symptom ques-
tionnaires: TNSS, total ocular symptom score (TOSS)15
and Other Allergic Rhinitis Symptom Score (OARSS),
in addition to a VAS for overall symptom severity. The use
of allergy and non-allergy-related medications were also
recorded in the diary.

2.4 | Sample collection and laboratory
analysis

A screening blood sample was collected and the follow-
ing tests conducted: full blood count, white cell differ-
ential, erythrocyte sedimentation rate (ESR), and specific
IgE to dust mites (D. pteronyssinus and D. farinae.) and
grain pollen mix (Bermuda, Timothy, Meadow, Johnson,
Rye and Paspalum) (QML Pathology). For those in-
dividuals who met the inclusion criteria nasal washing
and brushing, and blood samples were collected at Day 0
and Day 7 visits as described previously.16 Briefly nasal
samples included both washing with 100 ml of
phosphate-buffered saline and brushing of the mucosa
between the nasal septum and inferior turbinate of each
nostril. Recovered washing and brushing material was
combined and cellular material concentrated by cen-
trifugation. The cell pellet was directly lyzed using a
commercially available lysis buffer (RLT; Qiagen) and
the lysate was stored frozen until gene expression
analysis. For whole blood samples, RNA was extracted
from PAXgene tubes using a Maxwell® RSC automated
RNA extraction instrument using the commercially
available Maxwell® RSC miRNA Tissue Kit (Promega
Corporation).

2.5 | Gene expression analysis

Immune gene expression analysis of nasal cell lysate and
extracted RNA from blood was performed using a com-
mercially available NanoString nCounter PanCancer
Immune Profiling panel (NanoString Technologies). This
panel contained 40 references (housekeeping) genes and
730 immune genes and was used in combination with the
nCounter panel plus probe set which contained an ad-
ditional 30 immune genes relating to the allergic re-
response and mechanism of action of steroids and anti-
histamines (760 immune genes in total). Gene ex-
pression data underwent imaging quality control and
normalization checks before analysis and interpretation
of data. Genes that were expressed at counts below 20 in
80% or more samples were excluded from further ana-
lysis. Reference (housekeeping) normalization was per-
formed using the GeNorm Algorithm where 20 out of 40
housekeeping genes were used for the nasal lysate sam-
plies and 33/40 housekeeping genes were used for the
peripheral blood samples.

2.6 | Statistical analysis

Based on a standard deviation of gene expression in-
tensity of 0.6, an α of 0.001, and at least two-fold differ-
ence in gene expression, a sample size of 16 patients per
group was estimated to achieve 95% power. Differences
in demographic and clinical measures between groups
were assessed with a one-way analysis of covariance and a
χ² test for categorical variables. Variables were log-
transformed where appropriate to approximate a normal
distribution. Change (pre-post) in symptom severity
questionnaires was measured with an paired t-test. Dif-
fences in absolute change in symptom severity ques-
tionnaires between groups were measured with a paired t-test. Dif-
fences in absolute change in symptom severity ques-
tionnaires between groups were measured with an analysis of covariance with baseline score as the covari-
ate. Differentially expressed genes were identified using
R package Limma,17 where moderated t-tests were per-
formed to compare the gene expression levels between
groups. The significantly differentially expressed genes
(p < .05) in each treatment group were assessed for en-
richment into Reactome pathways. Statistical sig-
ificance of all clinical measures differentially expressed
genes and pathway enrichment was accepted at p < .05.
FIGURE 1 Consort diagram depicting flow and retention of study participants FP, fluticasone propionate “Flixonase” group; AZE/FP, azelastine/fluticasone propionate “Dymista” group; and AZE, azelastine “Azep” group

3 | RESULTS

3.1 | Study cohort

Forty-eight participants were randomized to the study. Two participants did not complete the treatment period and were withdrawn (Figure 1). Reasons for withdrawal included the development of the ear infection in one participant and an unexpected adverse event considered unrelated to the intervention in a second participant that prevented compliance with the study protocol. The demographic and baseline characteristics of the study groups based on a per-protocol analysis are given in Table 1. The groups were matched with the exception of blood eosinophil counts which were significantly different between the FP and AZE groups.

Treatments were well tolerated by participants. Adverse events were mild, with minimal impact on daily activities, were consistent with previously reported findings and are presented in Table S1.

Self-reported compliance was 96% ± 6% of total scheduled doses for the FP group, 96% ± 6% for the AZE/FP group, and 99% ± 3% for the AZE group. All participants administered ≥86%. Compliance was verified from weights of returned medications and ranged from 81% (AZE group) to 93% (AZE/FP group) missing less than two doses.

Eight of the participants reported needing to follow the rescue medication strategy during the 7-day intervention period. For five of these participants (two from the FP group, one from the AZE/FP group, and two from the AZE group) this included use of nasal irrigation only. One participant (FP group) reported use of a nasal decongestant, one participant (FP group) reported use of oral antihistamines, and one participant (AZE group) reported use of eye drops.

3.2 | Symptom assessment

All symptom severity measures were significantly improved following treatment in all groups (Table S2). mRQLQ improvement was significantly greater in AZE/FP compared with AZE (p = .014) (Figure 2). Both FP (p = .013) and AZE/FP (p = .016) treatments had a significantly greater effect on TNSS improvement when compared to AZE. Improvement in OARSS was significantly greater in FP (p = .029) and AZE/FP (p = .044) when compared with the AZE. Reduction in overall symptom severity (based on VAS) was greater in the AZE/FP (p = .022) and FP (p = .040) when compared with AZE.

3.3 | Differentially expressed genes

Demographic and clinical characteristics of the subjects who had samples that met the quality control criteria for gene expression studies were not different from the per-protocol population.

3.3.1 | Nasal mucosa

Nasal lysate samples from 13 FP, 11 AZE/FP, and 11 AZE participants were available for analysis (Table S3). A total of 588 genes included in the NanoString nCounter panel were expressed above background. FP had a strong downregulatory effect on gene expression, while AZE/FP and AZE had a mostly upregulatory effect on immune gene expression (Figure 3). The top 10 differentially expressed genes for all treatment groups are shown in Table 2.
FP had the greatest effect on immune gene expression, with 206 immune genes differentially expressed at \( p < .05 \) following treatment. Of these 206 differentially expressed genes (DEGs), 24 immune genes were upregulated (0.49–1.40 Log2 FC), and 182 immune genes were downregulated (−2.57 to −0.45 Log2 FC). For AZE/FP, a total of 16 immune genes were differentially expressed following treatment (\( p < .05 \)); 10 genes were downregulated (−1.53 to −0.58 Log2 FC) and six genes were upregulated (1.07–1.62 Log2 FC). AZE had the least effect on immune gene expression; five immune genes were differentially expressed (\( p < .05 \)) following treatment; one gene was downregulated (−1.68 Log2 FC) and four immune genes were upregulated (0.59 to 1.19 Log2 FC).

### TABLE 1  Baseline demographic and clinical measures for the per-protocol population

|                      | FP     | AZE/FP | AZE    | \( p \) value |
|----------------------|--------|--------|--------|---------------|
| **n**                | 14     | 16     | 16     | –             |
| **Age (years)**      | 37.63 ± 14.60 | 39.42 ± 10.03 | 37.26 ± 15.08 | .889          |
| **Sex F/M (% female)** | 10/4 (71%) | 10/6 (63%) | 11/5 (69%) | .864          |
| **Height (cm)**      | 169.11 ± 9.35 | 171.03 ± 10.26 | 171.94 ± 8.63 | .710          |
| **Weight (kg)**      | 76.69 ± 15.72 | 72.16 ± 15.33 | 73.46 ± 13.20 | .694          |
| **BMI (kg/m²)**      | 26.65 ± 3.95 | 24.45 ± 3.37 | 24.78 ± 3.64 | .226          |
| **Ethnicity (% Caucasian)** | 78.60% | 68.80% | 87.50% | .437          |
| **Immune measures (Day-14)** |        |        |        |               |
| White cell count (×10⁹/L) | 7.18 ± 1.70 | 6.98 ± 2.09 | 5.90 ± 1.50 | .112          |
| Lymphocytes (×10⁹/L) | 2.32 ± 0.80 | 2.26 ± 0.73 | 1.98 ± 0.63 | .366          |
| Eosinophils (×10⁹/L) | 0.53 ± 0.37 | 0.44 ± 0.30 | 0.26 ± 0.16 | .038          |
| Neutrophils (×10⁹/L) | 3.74 ± 1.22 | 3.68 ± 1.33 | 3.18 ± 1.00 | .366          |
| Basophils (×10⁹/L)  | 0.06 ± 0.05 | 0.07 ± 0.03 | 0.04 ± 0.03 | .085          |
| ESR (mm/h)           | 14.50 ± 13.78 | 7.94 ± 6.17 | 7.94 ± 8.27 | .267          |
| **Allergen sensitivity (Day-14)** |        |        |        |               |
| Co-allergy to dust mites and pollen (%) | 50% | 62.50% | 62.50% | .731          |
| IgE Dermatophagoides pteronyssinus (kU/L) | 39.28 ± 40.39 | 17.12 ± 21.60 | 11.37 ± 20.34 | .088          |
| IgE D. farinae (kU/L) | 35.11 ± 39.85 | 13.41 ± 18.31 | 8.56 ± 17.31 | .093          |
| IgE grass pollen mix (kU/L) | 2.13 ± 4.29 | 10.44 ± 25.84 | 6.20 ± 21.29 | .526          |
| IgG4 D. pteronyssinus (kU/L) | 0.50 ± 0.54 | 0.47 ± 0.42 | 0.38 ± 0.43 | .772          |
| IgG4 D. farinae (kU/L) | 0.42 ± 0.42 | 0.39 ± 0.26 | 0.30 ± 0.38 | .617          |
| IgG4 grass pollen mix (kU/L) | 0.67 ± 0.35 | 1.07 ± 0.97 | 0.80 ± 0.66 | .469          |
| **Symptom severity (Day 0)** |        |        |        |               |
| Total Nasal Symptom Score (0–12 U) | 5.93 ± 3.95 | 4.00 ± 1.86 | 7.06 ± 3.64 | .299          |
| Total Ocular Symptom Score (0–9 U) | 3.57 ± 2.44 | 2.00 ± 2.00 | 3.19 ± 2.74 | .182          |
| mRQLQ Score (0–6 U) | 2.90 ± 1.25 | 2.66 ± 0.79 | 3.00 ± 1.12 | .653          |
| Other allergic rhinitis symptoms (0–12 U) | 4.51 ± 3.89 | 3.07 ± 2.16 | 5.21 ± 3.47 | .865          |
| Visual Analog Scale (0–100 mm) | 54.18 ± 33.51 | 48.16 ± 22.31 | 60.50 ± 30.10 | .485          |
| **Medication Usage (Day 14–Day 0)** |        |        |        |               |
| Allergy medication use; % of total diary responses (washout period) | 0.37 ± 0.29 | 0.25 ± 0.20 | 0.40 ± 0.31 | .237          |

Abbreviations: AZE, azelastine “Azep” group; AZE/FP, azelastine/fluticasone propionate “Dymista” group; FP, fluticasone propionate “Flixonase” Group; mRQLQ, miniRhinoconjunctivitis quality of life.
3.3.2 | Blood

Blood samples from 13 FP, 16 AZE/FP, and 15 AZE participants were available for analysis (Table S4). The number of DEGs from blood samples was lower than that observed in nasal lysate samples with 485 genes from the NanoString nCounter panel expressed above background. The top 20 differentially expressed genes for each treatment group are shown in Table 2. Treatment with FP had the greatest effect on immune gene expression, with 34 genes differentially expressed ($p < .05$); six genes were downregulated ($−0.47$ to $−0.15 \log_2$ FC) and 24 genes were upregulated ($0.16$ – $0.50 \log_2$ FC). For AZE/FP, a total of 18 genes were differentially expressed ($p < .05$) following treatment; nine genes were downregulated ($−0.26$ to $−0.15 \log_2$ FC) and nine were upregulated ($0.12$ – $0.20 \log_2$ FC). For AZE, a total of 20 genes were differentially expressed ($p < .05$); six genes were downregulated ($−0.44$ to $−0.15 \log_2$ FC) and 14 genes were upregulated ($0.13$ – $0.43 \log_2$ FC). Given the modest impacts of treatment on differential gene expression in blood samples, additional analyses were not performed.

3.4 | Comparison of immune gene expression between treatment groups

Four DEGs were in common between AZE/FP and FP; TPSAB1, NOS2, CD274, and TNFSF13 all which were downregulated in both treatment groups (Table 3). There were no DEGs in common between AZE/FP and AZE, or between FP and AZE. For those DEGs identified for each of the treatments, the gene expression fold change was compared with the other treatment groups. The difference in fold change values between FP and AZE was the greatest, with 126 genes significantly different between these groups at $p < .05$ (Table S5). When comparing FP and AZE/FP, a total of 112 genes had significantly different FC values (Table S5). AZE/FP and AZE were the
most similar when comparing FC values, with only eight genes significantly different between groups (ST 5).

### 3.5 Pathway enrichment

The DEGs in the FP group were significantly enriched into 186 Reactome Pathways. The top four Reactome Pathways include Immune System, Cytokine Signaling in Immune system, Signaling by Interleukins, and Innate Immune System (Table 4). The DEGs in the AZE/FP group were significantly enriched into four Reactome Pathways (Table 4) including Hemostasis, Immune System, Cytokine Signaling in Immune System, and PI3P, PP2A, and IER3 Regulate PI3K/AKT Signaling. These four enriched pathways were also significantly enriched in the FP group (data not shown). The DEGs in the AZE group were not enriched into any Reactome Pathways.

### 4 DISCUSSION

The combination AZE/FP nasal spray has been reported to be significantly more effective at reducing self-reported AR symptoms than treatment with either agent alone. The biological basis for this enhanced AR symptom relief is unknown. The current study used a parallel-group design to compare the immune gene expression profiles of nasal lysate samples from AR sufferers following administration with AZE/FP formulated together in comparison to products formulated with a single active ingredient (either AZE or FP alone) as control groups. AR symptoms significantly improved under all treatments, but the improvement was less pronounced with AZE.

A key finding in this study was distinct gene expression patterns between groups in response to treatment. FP had a strong downregulatory effect on gene expression, whilst effects of AZE/FP and AZE treatment were more modest with most DEGs being upregulated. A total of 206 DEGs were identified in the FP group. The majority of these were downregulated; consistent with the primary mechanism of action of corticosteroids. The top three downregulated DEGs were AMICA1, GZMB, and LTB. AMICA1, is involved in leukocyte migration and antigen processing and presentation pathways and its downregulation supports the potential for FP to modulate the early stages of the allergic response. Indeed, the high-affinity IgE receptor (FCER1A gene), important for mast cell sensitization, was also significantly downregulated by FP treatment. Downregulation of GZMB by corticosteroids has been previously reported. Granzyme B is a serine protease encoded by the GZMB gene, is expressed by a range of immune cells including mast cells and is also involved in extracellular matrix proteolysis and cytokine processing. The LTB gene encodes lymphotixin beta which is a member of the TNF cytokine family. Binding of lymphotxin β to the LTβ receptor induces activation of transcription factor NF-κB which is involved in the expression of many pro-inflammatory molecules pertinent to the allergic response. Hence, downregulation of this gene could result in moderation of the inflammation associated with the allergic response.

AZE had only modest effects on gene expression compared with the other treatments with only five genes differentially expressed. This finding is consistent with the known mechanism of antihistamines, whereby antihistamines interact specifically with histamine receptors, rather than exhibiting broad immune-modulatory action. The top three DEGs following treatment with AZE were APOE, TPTE, and CAMP. Apolipoprotein E (APOE) is involved in the capture and delivery of lipid antigens to antigen-presenting cells. Downregulation of APOE may provide symptomatic relief through preventing enhanced antigen presentation and downstream allergic inflammation. The TPTE gene is involved in signal transduction pathways, however, its specific role in allergic
| Gene         | Log2 fold change | Linear fold change | Lower confidence limit (log2) | Upper confidence limit (log2) | p value    | p adjust   |
|--------------|------------------|--------------------|------------------------------|-------------------------------|------------|------------|
| Nasal mucosa samples |                  |                    |                              |                               |            |            |
| AMICA1      | −2.46            | 0.18               | −3.10                        | −1.83                         | 3.16 × 10⁻⁷| 1.86 × 10⁻⁴|
| GZMB        | −2.54            | 0.17               | −3.30                        | −1.78                         | 2.37 × 10⁻⁶| 6.96 × 10⁻⁴|
| LTB         | −2.41            | 0.19               | −3.20                        | −1.62                         | 6.83 × 10⁻⁶| 1.03 × 10⁻³|
| FCER1A      | −2.55            | 0.17               | −3.38                        | −1.71                         | 7.03 × 10⁻⁶| 1.03 × 10⁻³|
| SOCS1       | −2.20            | 0.22               | −3.01                        | −1.40                         | 2.49 × 10⁻⁵| 2.92 × 10⁻³|
| PTGDR2      | −2.29            | 0.20               | −3.20                        | −1.38                         | 6.19 × 10⁻⁵| 5.43 × 10⁻³|
| IL1RL1      | −2.36            | 0.19               | −3.33                        | −1.40                         | 8.39 × 10⁻⁵| 5.43 × 10⁻³|
| HLA-DRA     | −1.75            | 0.30               | −2.47                        | −1.03                         | 9.22 × 10⁻⁵| 5.43 × 10⁻³|
| CXCR3       | −2.04            | 0.24               | −2.89                        | −1.19                         | 1.02 × 10⁻⁴| 5.43 × 10⁻³|
| CD1C        | −1.62            | 0.33               | −2.30                        | −0.94                         | 1.07 × 10⁻⁴| 5.43 × 10⁻³|
| Peripheral blood samples |                  |                    |                              |                               |            |            |
| IL3RA       | −0.47            | 0.72               | −0.65                        | −0.29                         | 4.95 × 10⁻⁵| 2.40 × 10⁻²|
| IL1B        | 0.33             | 1.26               | 0.15                         | 0.51                          | 1.20 × 10⁻⁵| 2.91 × 10⁻¹|
| MS4A2       | −0.38            | 0.77               | −0.62                        | −0.14                         | 4.45 × 10⁻³| 5.14 × 10⁻¹|
| IL5RA       | −0.33            | 0.79               | −0.55                        | −0.12                         | 5.08 × 10⁻³| 5.14 × 10⁻¹|
| NFKB1       | 0.22             | 1.16               | 0.07                         | 0.37                          | 6.29 × 10⁻³| 5.14 × 10⁻¹|
| RNASE3      | −0.47            | 0.72               | −0.79                        | −0.15                         | 7.12 × 10⁻³| 5.14 × 10⁻¹|
| HRH4        | −0.29            | 0.82               | −0.49                        | −0.09                         | 7.43 × 10⁻³| 5.14 × 10⁻¹|
| CD24        | −0.45            | 0.73               | −0.77                        | −0.13                         | 9.39 × 10⁻³| 5.61 × 10⁻¹|
| SLPI        | 0.30             | 1.23               | 0.08                         | 0.52                          | 1.04 × 10⁻²| 5.61 × 10⁻¹|
| NFKB2       | 0.20             | 1.15               | 0.05                         | 0.34                          | 1.22 × 10⁻²| 5.91 × 10⁻¹|
| Nasal mucosa samples |                  |                    |                              |                               |            |            |
| TNFSF10     | −0.92            | 0.53               | −1.48                        | −0.36                         | 3.58 × 10⁻³| 9.85 × 10⁻¹|
| NOS2A       | −1.53            | 0.35               | −2.57                        | −0.49                         | 7.43 × 10⁻³| 9.85 × 10⁻¹|
| PPBP        | 1.52             | 2.87               | 0.48                         | 2.57                          | 7.66 × 10⁻³| 9.85 × 10⁻¹|
| ABCB1       | 1.23             | 2.35               | 0.32                         | 2.14                          | 1.17 × 10⁻²| 9.85 × 10⁻¹|
| KIT         | −0.98            | 0.51               | −1.76                        | −0.21                         | 1.66 × 10⁻²| 9.85 × 10⁻¹|
| IFNA8       | 1.40             | 2.64               | 0.25                         | 2.55                          | 2.10 × 10⁻²| 9.85 × 10⁻¹|
| IL33        | −1.07            | 0.47               | −1.97                        | −0.18                         | 2.25 × 10⁻²| 9.85 × 10⁻¹|
| CD274       | −0.98            | 0.51               | −1.82                        | −0.14                         | 2.62 × 10⁻²| 9.85 × 10⁻¹|
| TNFSF13     | −0.83            | 0.56               | −1.55                        | −0.11                         | 2.65 × 10⁻²| 9.85 × 10⁻¹|
| TPSAB1      | −1.12            | 0.46               | −2.17                        | −0.07                         | 3.81 × 10⁻²| 9.85 × 10⁻¹|
| Peripheral blood samples |                  |                    |                              |                               |            |            |
| CXCR6       | −0.26            | 0.84               | −0.43                        | −0.08                         | 7.35 × 10⁻³| 9.43 × 10⁻¹|
| CLEC4C      | −0.25            | 0.84               | −0.44                        | −0.06                         | 1.12 × 10⁻²| 9.43 × 10⁻¹|
| LY9         | 0.17             | 1.12               | 0.04                         | 0.30                          | 1.33 × 10⁻²| 9.43 × 10⁻¹|
| ITK         | 0.17             | 1.12               | 0.03                         | 0.30                          | 1.78 × 10⁻²| 9.43 × 10⁻¹|

**Table 2** Top 10 differentially expressed genes in nasal lysate and blood samples for the three treatment groups
disease is not known. The CAMP gene encodes the cathelicidin-related antimicrobial peptides and was upregulated following treatment with AZE. Cathelicidin has antimicrobial and immunoregulatory functions. Reduced levels of cathelicidin were observed in the nasal lavage fluid of children suffering AR compared with controls, indicating that cathelicidin may be involved in the pathogenesis of AR.

Of the 16 DEGs in response to AZE/FP, six were upregulated and 10 downregulated. The top three downregulated DEGs included TNFSF10, NOS2A, and PPBP. TNFSF10 induces the activation of transcription factor NF-κB a known driver of inflammatory pathways pertinent to the allergic response. A TNFSF10 knockout mouse-model has been found to have reduced airway hyperactivity, peribronchial eosinophilia, and levels of mast cells in the airways compared with wild-type mice. As such, downregulation of this gene could contribute to the improvement of AR symptoms. NOS2A encodes a nitric oxide synthase with the increased

| Gene     | Log2 fold change | Linear fold change | Lower confidence limit (log2) | Upper confidence limit (log2) | p value       | p adjust       |
|----------|------------------|--------------------|------------------------------|-------------------------------|---------------|---------------|
| PNMA1    | −0.16            | 0.90               | −0.29                        | −0.03                         | 1.89 × 10⁻²   | 9.43 × 10⁻¹   |
| CSF1     | −0.25            | 0.84               | −0.46                        | −0.04                         | 2.11 × 10⁻²   | 9.43 × 10⁻¹   |
| FAS      | −0.23            | 0.85               | −0.42                        | −0.04                         | 2.13 × 10⁻²   | 9.43 × 10⁻¹   |
| PVR      | −0.19            | 0.88               | −0.36                        | −0.03                         | 2.54 × 10⁻²   | 9.43 × 10⁻¹   |
| AKT3     | 0.12             | 1.09               | 0.01                         | 0.23                          | 3.34 × 10⁻²   | 9.43 × 10⁻¹   |
| CD59     | −0.19            | 0.88               | −0.36                        | −0.01                         | 3.51 × 10⁻²   | 9.43 × 10⁻¹   |

### AZE Group

#### Nasal mucosa samples

| Gene     | Log2 fold change | Linear fold change | Lower confidence limit (log2) | Upper confidence limit (log2) | p value       | p adjust       |
|----------|------------------|--------------------|------------------------------|-------------------------------|---------------|---------------|
| APOE     | −1.68            | 0.31               | −2.93                        | −0.43                         | 1.19 × 10⁻²   | 9.90 × 10⁻¹   |
| TPTE     | 1.00             | 2.00               | 0.20                         | 1.81                          | 1.84 × 10⁻²   | 9.90 × 10⁻¹   |
| CAMP     | 1.19             | 2.28               | 0.12                         | 2.26                          | 3.15 × 10⁻²   | 9.90 × 10⁻¹   |
| CD27     | 0.59             | 1.51               | 0.03                         | 1.16                          | 3.94 × 10⁻²   | 9.90 × 10⁻¹   |
| IL23A    | 0.59             | 1.50               | 0.03                         | 1.15                          | 4.02 × 10⁻²   | 9.90 × 10⁻¹   |
| IL18RAP  | 1.13             | 2.19               | −0.03                        | 2.30                          | 5.56 × 10⁻²   | 9.90 × 10⁻¹   |
| C4B      | 0.46             | 1.37               | −0.04                        | 0.95                          | 6.71 × 10⁻²   | 9.90 × 10⁻¹   |
| CCR2     | 0.60             | 1.52               | −0.08                        | 1.28                          | 7.84 × 10⁻²   | 9.90 × 10⁻¹   |
| CT45A1   | 0.70             | 1.62               | −0.09                        | 1.49                          | 7.86 × 10⁻²   | 9.90 × 10⁻¹   |
| IL18     | −0.43            | 0.74               | −0.92                        | 0.06                          | 7.99 × 10⁻²   | 9.90 × 10⁻¹   |

#### Peripheral blood samples

| Gene     | Log2 fold change | Linear fold change | Lower confidence limit (log2) | Upper confidence limit (log2) | p value       | p adjust       |
|----------|------------------|--------------------|------------------------------|-------------------------------|---------------|---------------|
| NT5E     | 0.39             | 1.31               | 0.15                         | 0.62                          | 2.66 × 10⁻³   | 9.54 × 10⁻¹   |
| SPN      | 0.40             | 1.32               | 0.11                         | 0.69                          | 1.02 × 10⁻²   | 9.54 × 10⁻¹   |
| ITGAL    | 0.17             | 1.13               | 0.04                         | 0.30                          | 1.07 × 10⁻²   | 9.54 × 10⁻¹   |
| CCR2     | −0.35            | 0.78               | −0.62                        | −0.08                         | 1.34 × 10⁻²   | 9.54 × 10⁻¹   |
| IL2RB    | 0.25             | 1.19               | 0.05                         | 0.45                          | 1.53 × 10⁻²   | 9.54 × 10⁻¹   |
| CEACAM8  | −0.44            | 0.74               | −0.79                        | −0.09                         | 1.60 × 10⁻²   | 9.54 × 10⁻¹   |
| FYN      | 0.13             | 1.09               | 0.03                         | 0.23                          | 1.68 × 10⁻²   | 9.54 × 10⁻¹   |
| OAS3     | 0.30             | 1.23               | 0.05                         | 0.55                          | 1.97 × 10⁻²   | 9.54 × 10⁻¹   |
| SLC11A1  | −0.22            | 0.86               | −0.40                        | −0.03                         | 2.50 × 10⁻²   | 9.54 × 10⁻¹   |
| IL6ST    | 0.16             | 1.12               | 0.02                         | 0.30                          | 2.59 × 10⁻²   | 9.54 × 10⁻¹   |
expression of NOS2A identified in bronchial biopsy samples from allergic asthmatics compared with healthy controls downregulated following use of inhaled corticosteroids. Pro-Platelet Basic Protein (PPBP) is a powerful chemoattractant and activator for neutrophils and has been previously reported to be downregulated by glucocorticoids. Neutrophils contribute to allergic inflammation via the release of reactive oxygen species and proteases which damage the nasal epithelium and promote migration of effector cells. Reduced neutrophil infiltration in the nasal mucosa as a result of reduced PPBP expression would likely confer reductions in AR symptoms.

The DEGs in response to FP and AZE/FP were found to be enriched into Reactome pathways. As was expected based simply on total number of DEGs, the DEGs in the FP group were enriched into a greater number of pathways than the DEGs in the AZE/FP. In contrast, the DEGs in the AZE group were not enriched into any Reactome pathways, given the limited numbers of genes involved. This result confirms that AZE acts on a small number of distinct genes to exert its clinical effects rather than modulating many genes within a single, or multiple concurrent pathways. In addition to the identification of some shared Reactome pathways, genes that were common between treatments were also explored. It was surprising to note that only four DEGs (TPSAB1, NOS2, CD274, and TNFSF13) were shared between FP and AZE/FP. All four genes were downregulated and it was noted that the FC values for NOS2, CD274, and TNFSF13 were lower in the AZE/FP group compared with FP or AZE alone, indicating possible synergistic effects. Furthermore, some 112 DEGs were expressed significantly differently between AZE/FP and FP confirming unique and not simply additive effects on immune regulatory pathways between these treatments. In contrast, AZE/FP
and AZE were more similar when comparing the fold change values of DEG with only eight genes significantly different between groups. The difference in modulation of these eight genes between AZE/FP and AZE may explain the enhanced clinical effects of AZE/FP compared to AZE. Finally, the lack of shared DEGs between the FP and AZE group was anticipated given the known distinct mechanisms of action of these two drugs. Indeed, among the DEGs, 126 genes were significantly differentially regulated between FP and AZE.

In comparison to nasal lysate samples, there were limited effects of FP, AZE/FP, and AZE on gene expression in peripheral blood samples. Both numbers of DEGs and FC values were attenuated in peripheral blood. The translation of these small changes in gene expression to substantial protein production and meaningful clinical effects is generally considered unlikely. Indeed, second generation steroids such as FP have an estimated systemic bioavailability of less than 1% and systemic adverse events are considered rare. Intranasal application of a single dose of FP and Rhinocort (Budesonide) had no significant effect on peripheral blood lymphocyte populations of healthy individuals. Similarly, the small gene expression changes in blood samples following nasal spray administration reported here, may be indicative of some carry-over effects from the topical site, but suggest that broad systemic effects as a result of topical administration are unlikely.

AZE/FP and FP had comparable effects on symptom relief. However, it is acknowledged that this study was not powered to detect statistically significant differences in clinical outcome between treatments. Similarly, if the documented symptomatic relief exceeded natural day-to-day variation in self-reported symptoms is unclear in the absence of a placebo control. Regardless, the observations of greater reductions in self-reported symptoms in response to FP and AZE/FP when compared to AZE alone are consistent with other published studies. Despite the comparable effects of AZE/FP and FP alone on symptom relief, effects on immune-gene expression were not similar. Of particular interest, the combination AZE/FP spray, whilst achieving comparable symptom reduction to FP, did not induce greater changes in gene expression than either treatment alone, that is simple additive effects on gene expression were not observed. The moderate degree of modulation of genes by AZE/FP suggests than in combination, alternative pathways may underpin the observed reduction in symptoms, while mitigating a broader local immunosuppressive effect.

The current study was unique in its assessment of patterns of immune gene expression in response to pharmaceutical treatment at the site of application, the nasal mucosa, in individuals who were well characterized for allergic disease. Furthermore, by comparing the combination product to the single active ingredient formulations in our parallel-group design, we were able to directly assess different gene expression patterns between treatments. It is however recognized that many of the DEGs identified in this study did not reach statistical significance when adjusted for false discovery rate and as such additional studies are needed to confirm the validity of the DEGs including with the further addition of a placebo control. In addition, the effect of the intranasal sprays on immune gene expression was evaluated at a single time point only (day 7); this limitation could be overcome and greater resolution of biological pathways may be achieved with serial sampling over the duration of the intervention. As this was a community-based study, the comparative effect of each nasal sprays on early-phase and late-phase allergic responses is not known and should be studied under conditions of controlled allergen exposure.

In conclusion, investigation of nasal mucosa samples of AR sufferers following the intranasal application of AZE/FP, compared to FP and AZE alone, revealed distinct gene expression patterns across treatments. The greatest distinction between gene expression profiles was between FP and AZE which is indicative of the different mechanisms of action between corticosteroids and antihistamines. A compelling finding of this study was that FP and AZE/FP both had moderate effects on symptom reduction, but had diverse effects on gene expression. FP had a strong downregulatory effect on gene expression compared with AZE/FP which had an intermediate effect on gene expression with a mix of downregulated and upregulated genes following treatment. The moderate number of genes modulated by AZE/FP appears to be sufficient to significantly reduce AR symptoms, whilst avoiding total suppression of the local mucosal immune system.

REGISTRATION
Australian and New Zealand Clinical Trial Registry (#ACTRN12616001439437).

ACKNOWLEDGMENTS
The authors acknowledge the support of the Queensland Allergy Services Clinic (Southport, QLD, Australia) for providing clinic access and for performing the skin prick tests. This study was funded by Mylan N.V.

CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.
AUTHOR CONTRIBUTIONS
Design: Annabelle M. Watts, Nicholas P. West, Amanda J. Cox, and Peter K. Smith. Data collection; Annabelle M. Watts and Amanda J. Cox; Experiments: Annabelle M. Watts. Data analysis: Annabelle M. Watts, Ping Zhang, and Nicholas P. West. Drafting of manuscript: Annabelle M. Watts and Amanda J. Cox. Manuscript revision and approval: all authors.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Allan W. Cripps https://orcid.org/0000-0002-8755-932X
Amanda J. Cox https://orcid.org/0000-0003-3684-0952

REFERENCES
1. Cook M, Douglass J, Mallon D, Mullins R, Smith J, M W. The economic impact of allergic disease in Australia: not to be sneezed at [report]. Australian Society of Clinical Immunology and Allergy. 2007.
2. Marcellusi A, Viti R, Incorvaia C, Mennini FS. Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study. Recenti Prog Med. 2015;106:517-527.
3. Zubervier T, Lotvall J, Simons S, Subramanian SV, Church MK. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy. 2014;69:1275-1279.
4. Pitman R, Paracha N, Parker C, Acaster S, Bachert C, Bousquet J. Episode pattern and healthcare utilisation in patients with seasonal allergic rhinitis. Allergy. 2012;67:1-687.
5. Fokkens WJ, Hellings PW. Rhinology in the forefront of European political attention. Rhinology. 2015;53:289.
6. Hampel FC, Ratner PH, Van Bavel J, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010;105:168-173.
7. Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012;33:324-332.
8. Ratner P, Hampel F, Breazna A, Caracta C, Tantry S. Efficacy and safety of olopatadine/mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2017;119:S90.
9. Ratner PH, Hampel F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100:74-81.
10. Bousquet J, Khalttaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160.
11. Downie SR, Andersson M, Rimmer J, et al. Symptoms of persistent allergic rhinitis during a full calendar year in house dust mite-sensitive subjects. Allergy. 2004;59:406-414.
12. Bousquet PJ, Combescure C, Neukirch F, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007;62:367-372.
13. National Health and Medical Research Council. Australian guidelines to reduce health risks from drinking alcohol NHMRC Canberra. 2009.
14. Juniper EF, Thompson AK, Ferrie PJ, Roberts NJ. Development and validation of the mini rhinoconjunctivitis quality of life questionnaire. Clin Exp Allergy. 2000;30:132-140.
15. Aneeza WH, Husain S, Rahman RA, Van Dort D, Abdullah A, Gendeh BS. Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis. Allergy Rhinol (Providence). 2013;4:e120-e126.
16. Watts AM, West NP, Cripps AW, Smith PK, Cox AJ. Distinct gene expression patterns between nasal mucosal cells and blood collected from allergic rhinitis sufferers. Int Arch Allergy Immunol. 2018;177:29-34.
17. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.
18. Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129:1282-1289.e10.
19. Watts AM, Cripps A, West N, Cox A. Modulation of allergic inflammation in the nasal mucosa of allergic rhinitis sufferers with topical pharmaceutical agents. Front Pharmacol. 2019;10:294.
20. Thomas SY, Whitehead GS, Takaku M, et al. MyD88-dependent dendritic and epithelial cell crosstalk orchestrates immune responses to allergens. Mucosal Immunol. 2018;11:796-810.
21. Wang H, Barrenäs F, Bruhn S, Mobini R, Benson M. Increased IFN-γ/gamma activity in seasonal allergic rhinitis is decreased by corticosteroid treatment. J Allergy Clin Immunol. 2009;124:1360-1362.
22. Zhao Y, Wang H, Gustafsson M, Muraro A, Bruhn S, Benson M. Combined multivariate and pathway analyses show that allergen-induced gene expression changes in CD4+ T cells are reversed by glucocorticoids. PLoS One. 2012;7:e39016.
23. Salvi V, Vermi W, Cavani A, et al. IL-21 may promote granzyme B-dependent NK/plasmacytoid dendritic cell functional interaction in cutaneous lupus erythematosus. J Invest Dermatol. 2017;137:1493-1500.
24. Trapani JA. Granzymes: a family of lymphocyte granule serine proteases. Genome Biol. 2001;2:1-7.
25. Afonina IS, Tynan GA, Logue SE, et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol Cell. 2011;44:265-278.
26. Froelich CJ, Pardo J, Simon MM. Granule-associated serine proteases: granzymes might not just be killer proteases. Trends Immunol. 2009;30:117-123.
27. Omoto Y, Yamanaka K, Tokime K, et al. Granzyme B is a novel interleukin-18 converting enzyme. *J Dermatol Sci*. 2010;59:129-135.

28. Dejardin E, Droin NM, Delhase M, et al. The lymphotxin-β receptor induces different patterns of gene expression via two NF-xB pathways. *Immunity*. 2002;17:525-535.

29. VanArsdale TL, VanArsdale SL, Force WR, et al. Lymphotoxin-β receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor xB. *Proc Natl Acad Sci USA*. 1997;94:2460-2465.

30. van den Elzen P, Garg S, León L, et al. Apolipoprotein-mediated pathways of lipid antigen presentation. *Nature*. 2005;437:906-910.

31. Bandurska K, Berdowska A, Barczyńska-Felusiak R, Krupa P. Unique features of human cathelicidin LL-37. *Biofactors*. 2015;41:289-300.

32. Davidson DJ, Currie AJ, Reid GS, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. *J Immunol*. 2004;172:1146-1156.

33. Dilek F, Gultepe B, Ozkaya E, Yazici M, Gedik AH, Cakir E. Beyond anti-microbial properties: the role of cathelicidin in allergic rhinitis. *Allergol Immunopathol (Madr)*. 2016;44:297-302.

34. Collison A, Li J, Pereira de Siqueira A, et al. Tumor necrosis factor-related apoptosis-inducing ligand regulates hallmark features of airways remodeling in allergic airways disease. *Am J Respir Cell Mol Biol*. 2014;51:86-93.

35. Laprise C, Sladek R, Ponton A, Bernier M-C, Hudson TJ, Laviolette M. Functional classes of bronchial mucosa genes that are differentially expressed in asthma. *BMC Genomics*. 2004;5:21.

36. El-Gedaily A, Schoodon G, Schneemann M, Schaffner A. Constitutive and regulated expression of platelet basic protein in human monocytes. *J Leukoc Biol*. 2004;75:495-503.

37. Fransson M, Benson M, Wennergren G, Cardell L-O. A role for neutrophils in intermittent allergic rhinitis. *Acta Otolaryngol*. 2004;124:616-620.

38. Monteseirin J. Neutrophils and asthma. *J Investig Allergol Clin Immunol*. 2009;19:340-354.

39. Gupta R, Fonacier LS. Adverse Effects of Nonsystemic Steroids (Inhaled, Intranasal, and Cutaneous): a review of the literature and suggested monitoring tool. *Curr Allergy Asthma Rep*. 2016;16:44.

40. Fokkens WJ, van de Merwe JP, Braat JP, Overbeek SE, Hooijkaas H. The effect of intranasal and inhaled corticosteroids in healthy volunteers on the number of circulating lymphocytes and lymphocyte subsets. *Allergy*. 1999;54:158-164.

41. Kyrizakisl DE, Papadakis CE, Lohuiss PJ, Manolarakis G, Karakostasl E, Amanakis Z. Acute candidiasis of the oro-and hypopharynx as the result of topical intranasal steroids. *Rhinology*. 1999;38:87-89.

42. Schaffner A. Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon. *J Clin Invest*. 1985;76:1755-1764.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Watts AM, West NP, Smith PK, Zhang P, Cripps AW, Cox AJ. Nasal immune gene expression in response to azelastine and fluticasone propionate combination or monotherapy. *Immun Inflamm Dis*. 2021;1-13. doi:10.1002/iid3.571